ArticleCell reports2024
Epigenomic signatures of sarcomatoid differentiation to guide the treatment of renal cell carcinoma.
Abstract read
In one paragraph
Article in Cell reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Prognostic significance of systemic immunoinflammatory biomarkers and pathological features in clear cell renal cell carcinoma: a multicenter study.Annals of medicine · 2026Trial
- Updates and controversies in contemporary grading of clear cell renal cell carcinoma and papillary renal cell carcinoma.Histopathology · 2026Review
- Targeting PLOD2 induces epithelioid differentiation and improves therapeutic response in sarcomatoid renal cell carcinoma.Journal of advanced research · 2026Article
- The seventh kidney cancer research summit: progress in accelerating cures.The oncologist · 2026Article
- Predicting immunotherapy benefit in leiomyosarcoma through active chromatin cfDNA profiling.NPJ precision oncology · 2026Article
- Article
- Precision Oncology 2.0: Guiding Magic Bullets With Expression-Based Liquid Biopsy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- CREB5 regulates stem cell-like transcriptional programs to enhance tumor progression in prostate cancer.Oncotarget · 2026Article
- Liquid biopsy epigenetics: establishing a molecular profile based on cell-free DNA.Molecular oncology · 2026Review
- Cell-free DNA epigenomic profiling enables noninvasive detection and monitoring of translocation renal cell carcinoma.The Journal of clinical investigation · 2026Article
- Next-generation liquid biopsies: detecting circulating epigenetic changes to identify translocation renal cell carcinoma.The Journal of clinical investigation · 2026Article
- SNAP: Streamlined Nextflow Analysis Pipeline for Immunoprecipitation-Based Epigenomic Profiling of Circulating Chromatin.bioRxiv : the preprint server for biology · 2025Article
- Pericytes orchestrate a tumor-restraining microenvironment in glioblastoma.Nature communications · 2025Article
- HIF-2-Dependent Regulation of PTHrP and Paraneoplastic Hypercalcemia in Aggressive Clear-Cell Renal Cell Carcinoma.Cancer discovery · 2025Article
- Liquid biopsy - a narrative review with an update on current US governmental clinical trials targeting immunotherapy.Future science OA · 2025Review
- Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinoma.Cancer cell · 2025Article
- Molecular and therapeutic landscape of non-clear cell renal carcinoma.Nature reviews. Urology · 2025Review
- Review
- Plasma epigenomic profiling reveals treatment-emergent squamous transformation in prostate cancer.NPJ precision oncology · 2025Article
- CRISPR screening identifies regulators of enhancer-mediated androgen receptor transcription in advanced prostate cancer.Cell reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors.
Talal El ZarifDepartment of Internal Medicine, Yale School of Medicine, New Haven, CT, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
Karl SemaanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA; The Eli and Edythe L. Broad Institute, Cambridge, MA, USA.
Marc EidDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
Ji-Heui SeoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
Simon GarinetDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Matthew P DavidsohnDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Pranshu SahgalDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Brad FortunatoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
John CanniffDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Amin H NassarSection of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Sarah Abou AlaiwiSection of Cardiology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
Ziad BakounyDepartment of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Gitanjali LakshminarayananDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Hunter SavignanoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Kevin LyonsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sayed MatarDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Atef AliDepartment of Medicine, University of Minnesota Masonic Cancer Center, Minneapolis, MN, USA.
Eddy SaadDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Renee Maria SalibyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Paulo CordeiroDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA; The Eli and Edythe L. Broad Institute, Cambridge, MA, USA.
Ziwei ZhangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Nourhan El AhmarDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Yasmin Nabil LaimonDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Chris LabakiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
Valisha ShahDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Dory FreemanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jillian O'TooleDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Gwo-Shu Mary LeeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Justin HwangDepartment of Medicine, University of Minnesota Masonic Cancer Center, Minneapolis, MN, USA.
Mark PomerantzDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sabina SignorettiDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Eliezer M Van AllenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; The Eli and Edythe L. Broad Institute, Cambridge, MA, USA.
Wanling XieDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Jacob E BerchuckDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Srinivas R ViswanathanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
David A BraunSection of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA; Center of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Toni K ChoueiriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: toni_choueiri@dfci.harvard.edu.
Matthew L FreedmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: matthew_freedman@dfci.harvard.edu.
Sylvan C BacaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA; The Eli and Edythe L. Broad Institute, Cambridge, MA, USA. Electronic address: sylvan_baca@dfci.harvard.edu.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MVectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI JENNIFER W MACK · 1985 to 2026
$330.6MTreating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI David McDermott · 2003 to 2026
$53.4MPhysician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1M(PQ3) A functional genomic approach to identification and interpretation of germline-tumor genetic interactionsR01CA227237 · NCI · DANA-FARBER CANCER INST · PI GUSEV, ALEXANDER, ZAITLEN, NOAH A · 2018 to 2022
$3.5MElucidation of the genetic mechanisms driving prostate tumorigenesis through integrative computational and functional approachesR01CA251555 · NCI · DANA-FARBER CANCER INST · PI FREEDMAN, MATTHEW L, PASANIUC, BOGDAN · 2021 to 2025
$3.4MMolecular mechanisms and therapeutic targeting of activated NRF2 signaling in MiT/TFE translocation renal cell carcinomaR01CA279044 · NCI · DANA-FARBER CANCER INST · PI Srinivas Raghavan Viswanathan · 2023 to 2026
$2.0MNCI NIH HHS P30 CA006516NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA101942NCI NIH HHS R01 CA227237NCI NIH HHS R01 CA251555NCI NIH HHS R01 CA279044NCI NIH HHS T32 CA009172
Abstract
Renal cell carcinoma with sarcomatoid differentiation (sRCC) is associated with poor survival and a heightened response to immune checkpoint inhibitors (ICIs). Two major barriers to improving outcomes for sRCC are the limited understanding of its gene regulatory programs and the low diagnostic yield of tumor biopsies due to spatial heterogeneity. Herein, we characterized the epigenomic landscape of sRCC by profiling 107 epigenomic libraries from tissue and plasma samples from 50 patients with RCC and healthy volunteers. By profiling histone modifications and DNA methylation, we identified highly recurrent epigenomic reprogramming enriched in sRCC. Furthermore, CRISPRa experiments implicated the transcription factor FOSL1 in activating sRCC-associated gene regulatory programs, and FOSL1 expression was associated with the response to ICIs in RCC in two randomized clinical trials. Finally, we established a blood-based diagnostic approach using detectable sRCC epigenomic signatures in patient plasma, providing a framework for discovering epigenomic correlates of tumor histology via liquid biopsy.
Indexed as
Carcinoma, Renal CellEpigenomicsKidney NeoplasmsCell DifferentiationDNA MethylationEpigenesis, GeneticFemaleFos-Related Antigen 1Gene Expression Regulation, NeoplasticHumansMaleMiddle AgedProto-Oncogene Proteins c-fosFos-Related Antigen 1Proto-Oncogene Proteins c-fosCP: CancerCP: GenomicsepigenomicsFOSL1histone modificationsimmune checkpoint inhibitorsimmunotherapykidney cancerliquid biopsyrenal cell carcinomasarcomatoidtranscription factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.